183 related articles for article (PubMed ID: 10381291)
1. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Schaefer JR; Schweer H; Ikewaki K; Stracke H; Seyberth HJ; Kaffarnik H; Maisch B; Steinmetz A
Atherosclerosis; 1999 May; 144(1):177-84. PubMed ID: 10381291
[TBL] [Abstract][Full Text] [Related]
2. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Asztalos BF; Horvath KV; McNamara JR; Roheim PS; Rubinstein JJ; Schaefer EJ
Atherosclerosis; 2002 Oct; 164(2):361-9. PubMed ID: 12204809
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
4. Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit.
Rashid S; Uffelman KD; Barrett PH; Lewis GF
Circulation; 2002 Dec; 106(23):2955-60. PubMed ID: 12460878
[TBL] [Abstract][Full Text] [Related]
5. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
[TBL] [Abstract][Full Text] [Related]
6. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
7. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study.
Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
Int J Obes Relat Metab Disord; 2002 Sep; 26(9):1151-8. PubMed ID: 12187390
[TBL] [Abstract][Full Text] [Related]
8. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus.
Duvillard L; Pont F; Florentin E; Gambert P; Vergès B
Atherosclerosis; 2000 Sep; 152(1):229-37. PubMed ID: 10996359
[TBL] [Abstract][Full Text] [Related]
9. High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies.
Ooi EM; Watts GF; Farvid MS; Chan DC; Allen MC; Zilko SR; Barrett PH
Eur J Clin Invest; 2006 Sep; 36(9):626-32. PubMed ID: 16919045
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner.
Le NA; Diffenderfer MR; Thongtang N; Ooi EM; Barrett PH; Horvath KV; Dolnikowski GG; Asztalos BF; Schaefer EJ; Brown WV
Lipids; 2015 May; 50(5):447-58. PubMed ID: 25809021
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
12. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
13. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
Pietzsch J; Julius U; Nitzsche S; Hanefeld M
Diabetes; 1998 Dec; 47(12):1928-34. PubMed ID: 9836526
[TBL] [Abstract][Full Text] [Related]
14. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Rader DJ; Davidson MH; Caplan RJ; Pears JS
Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
[TBL] [Abstract][Full Text] [Related]
15. Increased production of HDL ApoA-I in homozygous familial defective ApoB-100.
Schaefer JR; Winkler K; Schweer H; Hoffmann MM; Soufi M; Scharnagl H; Maisch B; Wieland H; Steinmetz A; März W
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1796-9. PubMed ID: 10894819
[TBL] [Abstract][Full Text] [Related]
16. High-density lipoprotein apolipoprotein A-I kinetics in obesity.
Ooi EM; Watts GF; Farvid MS; Chan DC; Allen MC; Zilko SR; Barrett PH
Obes Res; 2005 Jun; 13(6):1008-16. PubMed ID: 15976143
[TBL] [Abstract][Full Text] [Related]
17. A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production.
Anthanont P; Polisecki E; Asztalos BF; Diffenderfer MR; Barrett PH; Millar JS; Billheimer J; Cuchel M; Rader DJ; Schaefer EJ
Atherosclerosis; 2014 Aug; 235(2):470-6. PubMed ID: 24950002
[TBL] [Abstract][Full Text] [Related]
18. Effect of fasting and feeding on apolipoprotein A-I kinetics in preβ
Chétiveaux M; Croyal M; Ouguerram K; Fall F; Flet L; Zair Y; Nobecourt E; Krempf M
Sci Rep; 2020 Sep; 10(1):15585. PubMed ID: 32973209
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
20. Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease.
Hancock-Cerutti W; Millar JS; Valentini S; Liu J; Billheimer JT; Rader DJ; Cuchel M
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
